Osimertinib in combination with pemetrexed, carboplatin and cisplatin are in clinical development as a first line treatment for metastatic, epidermal growth factor receptor (EGFR)-positive, non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Symptoms of lung cancer include cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. However, lung cancer may not always have symptoms early on. EGFR is a protein found on cells, which helps them grow therefore, mutation in the EGFR gene results in the uncontrolled cell growth leading to cancer. Osimertinib combined with platinum-based chemotherapy may offer a well-tolerated treatment option for EGFR NSCLC.
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation
Osimertinib in combination with pemetrexed, carboplatin and cisplatin are in clinical development as a first line treatment for metastatic, epidermal growth factor receptor (EGFR)-positive, non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites.
Interventions:
Carboplatin (Paraplatin)
, Cisplatin (Platinol)
, Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)
, Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2023